Formulation And Evaluation of Terbutaline Sulphate Tablet in The Sublingual Route for The Treatment of Asthma

Authors

  • Chand Ratan Rathi Research Scholar, Goenka College of Pharmacy, Lachhmangarh, Sikar
  • Vijay Sharma Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar
  • N Ravindra Principal and Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar
  • Sunil Kumawat Associate Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar

Abstract

Abstract:

Terbutaline sulphate is a selective B2 bronchodilator which is used in the treatment of asthma. Conventional Terbutaline tablets available in the market are not suitable where quick onset of action is required. Terbutaline sulphate sublingual tablets were prepared by using mannitol, microcrystalline cellulose pH102 (F1) and lactose monohydrate, microcrystalline cellulose pH102 (F4) as filler and its combination in different ratio, Crospovidone as super disintegrant and sodium lauryl Sulphate as permeability enhancers by drug dispersion direct compression method. The formulation F1 found the drug permeability, 8 seconds disintegration time and drug release within one minute. The formulation F4 also has drug permeability, 13 seconds disintegration time and 90.31% drug release within one minute. It was concluded that the sublingual tablet of Terbutaline sulphate can be formulated for sublingual absorption of drug in emergency treatment of asthma by Mannitol and Microcrystalline cellulose pH 102 in combination or lactose monohydrate and Microcrystalline cellulose pH 102 in combination as filler, Crospovidone a super disintegrant, and Sodium Lauryl sulphate as permeability enhancer by direct compression drug dispersion method.

Keywords: Dispersion method, drug permeability, sublingual, super disintegrant.

Downloads

Published

2024-12-24

How to Cite

Rathi , C. R., Sharma , V., N Ravindra, & Kumawat , S. (2024). Formulation And Evaluation of Terbutaline Sulphate Tablet in The Sublingual Route for The Treatment of Asthma. International Journal of Health Advancement and Clinical Research (tz), 2(4), 46–54. Retrieved from https://ijhacr.com/index.php/ijhacr/article/view/58

Most read articles by the same author(s)

1 2 > >>